We use cookies to ensure that we give you the best experience on our website Learn more

Jun 19, 2019

MASCC/ISOO Annual Meeting on Supportive Care in Cancer

06 - PREVALENCE AND PREDICTORS OF POST-TREATMENT PERIPHERAL NEUROPATHY IN SURVIVORS OF CANCER: RESULTS FROM THE 2010 LIVESTRONG SURVEY

;

peripheral neuropathy

survivorship

SES

Abstract

Abstract

thumbnail

Keywords

peripheral neuropathy

survivorship

SES

Abstract

Background: Peripheral Neuropathy (PN) is a common long-term effect of cancer treatment, but no study has reported results across a wide range of survivors. This study addresses that gap in the literature. Methods: Included in analyses were 3,061 post-treatment adult cancer survivors who completed the 2010 LIVESTRONG survey including items related to current and past PN, sociodemographics, cancer diagnosis and treatment. Respondents were excluded if they had metastatic/recurrent cancer or more than one primary cancer. Bi-variate and multivariate analyses were conducted to identify factors associated with post-treatment PN. Results: Participants were 49.1 (sd=11.8) years old and 4.8 (sd=5.4) years post-diagnosis. More than half were female (62.9%), married/partnered (70.6%), White (87.3%), college educated (52.9%), employed full-time (60.5%) and had health insurance (82.9 %). The most prevalent cancer types were: breast (29.9%), testicular (9.2%), and prostate (7.5%). Over half of participants received chemotherapy (57.9%) alone or in combination with radiation and/or surgery. Post-treatment PN was reported by 33.7% of survivors (n=1031); prevalence was highest among colorectal (63.9%), lung (60.8%), and ovarian (57.5%) cancer survivors. In logistic regression the strongest independent (p<.05) predictors were: chemotherapy [z(1)=177.1]; type of cancer [z(16)=38.4]; time since diagnosis [z(1)=26.7]; history of neuropathy prior to cancer [z(1)=24.7]; employment status [z(4)=17.28]; and income [z(6)=16.0]. Conclusions: A history of chemotherapy, certain cancer types, and PN prior to cancer were associated with higher risk for post-treatment PN. Time since diagnosis, full-time employment and higher income were associated with lower risk. Additional research is needed to determine whether these sociodemographic factors are predictors or consequences of post-treatment PN.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.